{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:52:26Z","timestamp":1783612346111,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Docetaxel is commonly used in breast cancer chemotherapy. The previous drug dose is generally calculated based on body surface area (BSA). However, the metabolism varies greatly among different patients. Docetaxel therapeutic drug monitoring (TDM) helps monitor adverse drug reactions and explore the appropriate range of area under the curve (AUC) to ensure chemotherapy effectiveness and reduce adverse reaction occurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a real-world retrospective study and included 180 breast cancer patients, who received a chemotherapy regimen containing docetaxel. The patients\u2019 demographic and tumor data were reviewed. Adverse reaction data during chemotherapy treatment were collected through patient questionnaires and laboratory test results. Univariate logistic regression analysis was performed on 33 patient indexes, including basic information, blood toxicity, liver and kidney function, gastrointestinal reactions, and cardiotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The adverse reactions of chemotherapy were matched with different docetaxel AUC results through univariate analysis. The patients between the groups were no statistically significant differences in terms of demographic and tumor data, including age, height, weight, BSA, and body mass index (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). Univariate analysis revealed significant differences in albumin (ALB) levels (<jats:italic>p<\/jats:italic> = 0.037), creatinine (CREA) levels (<jats:italic>p<\/jats:italic> = 0.002), nausea occurrence (<jats:italic>p<\/jats:italic> = 0.008), vomiting occurrence (<jats:italic>p<\/jats:italic> = 0.013), rashes occurrence (<jats:italic>p<\/jats:italic> = 0.002), and chemotherapy-induced alopecia incidence (CIA) (<jats:italic>p<\/jats:italic> = 0.002). Based on the results of the univariate analysis, binary logistic regression analysis was further conducted to identify predictors contributing to the occurrence of chemotherapy adverse reactions. The results demonstrated that an AUC value greater than 2.5\u00a0mg h\/L was significantly associated with increased risk of certain adverse reactions such as rashes, CIA, CREA, and ALB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The docetaxel TDM provides a reliable basis for monitoring chemotherapy adverse reactions, with high AUC significantly associated with certain adverse reactions. Future studies are expected to include more patients and conduct multi-center trials to obtain a suitable AUC range for Chinese patients, which will guide the determination of clinical chemotherapy doses and reduce the occurrence of adverse reactions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1563506","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:31:08Z","timestamp":1746768668000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Yongzhe","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Huai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bcp.15526","article-title":"A pharmacometrics model to define docetaxel target in early breast cancer","volume":"89","author":"Aldaz","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1200\/jco.2012.44.2863","article-title":"Body-surface area-based chemotherapy dosing: appropriate in the 21st century?","volume":"30","author":"Beumer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/s0140-6736(23)00285-4","article-title":"Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials","volume":"401","author":"Braybrooke","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/sonc.2001.22815","article-title":"Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer","volume":"28","author":"Burris","year":"2001","journal-title":"Seminars Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/03007995.2021.1929895","article-title":"Differences between the quality aspects of various generic and branded docetaxel formulations","volume":"37","author":"Chen","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","article-title":"Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience","volume":"9","author":"Crown","year":"2004","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103668","DOI":"10.1016\/j.breast.2023.103668","article-title":"Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide and epirubicin followed by docetaxel in patients with early breast cancer: a hellenic cooperative oncology group observational study (HE 10\/10) with concurrent investigation of significance of tumor infiltrating lymphocytes","volume":"73","author":"Dimitrakopoulos","year":"2024","journal-title":"Breast"},{"key":"B8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-015-3531-z","article-title":"The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis","volume":"153","author":"Do","year":"2015","journal-title":"Breast cancer Res. Treat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/1078-0432.Ccr-10-1636","article-title":"Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study","volume":"17","author":"Engels","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000366466","article-title":"Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia","volume":"9","author":"Fontanella","year":"2014","journal-title":"Breast Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1177\/1060028013509789","article-title":"Dosing considerations for obese patients receiving cancer chemotherapeutic agents","volume":"47","author":"Hall","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/jco.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J. Intern. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.6004\/jnccn.2017.7010","article-title":"Risk of febrile neutropenia associated with select myelosuppressive chemotherapy regimens in a large community-based oncology practice","volume":"15","author":"Li","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2165\/00003495-200565170-00007","article-title":"Docetaxel - a review of its use in metastatic breast cancer","volume":"65","author":"Lyseng-Williamson","year":"2005","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.21037\/atm.2020.01.76","article-title":"Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients","volume":"8","author":"Ma","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bcp.14678","article-title":"Role of TDM-based dose adjustments for taxane anticancer drugs","volume":"87","author":"Muth","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00228-016-2031-3","article-title":"Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach","volume":"72","author":"Onoue","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11096-010-9478-6","article-title":"Dose standardisation of anticancer drugs","volume":"33","author":"Pouliquen","year":"2011","journal-title":"Int. J. Clin. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"13241","DOI":"10.1038\/s41598-020-70187-8","article-title":"The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients","volume":"10","author":"Qi","year":"2020","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12967-020-02394-w","article-title":"Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study","volume":"18","author":"Sun","year":"2020","journal-title":"J. Transl. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/jco.2005.03.082","article-title":"Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly","volume":"23","author":"ten Tije","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.19401\/j.cnki.1007-3639.2023.12.004","article-title":"Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)","volume":"33","year":"2023","journal-title":"China Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.21037\/atm-22-2619","article-title":"Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients","volume":"10","author":"Wei","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/jco.2005.11.036","article-title":"Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol","volume":"23","author":"Yamamoto","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1563506\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:31:18Z","timestamp":1746768678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1563506\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":27,"alternative-id":["10.3389\/fphar.2025.1563506"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1563506","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1563506"}}